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iant axonal neuropathy (GAN), an autosomal re-
cessive disorder caused by mutations in 
 
GAN
 
,
is characterized cytopathologically by cytoskeletal
abnormality. Based on its sequence, gigaxonin contains an
NH
 
2
 
-terminal BTB domain followed by six kelch repeats,
which are believed to be important for protein–protein
interactions (Adams, J., R. Kelso, and L. Cooley. 2000.
 
Trends Cell Biol.
 
 10:17–24.). Here, we report the identiﬁca-
tion of a neuronal binding partner of gigaxonin. Results
obtained from yeast two-hybrid screening, cotransfections,
and coimmunoprecipitations demonstrate that gigaxonin
binds directly to microtubule-associated protein (MAP)1B
light chain (LC; MAP1B-LC), a protein involved in maintain-
ing the integrity of cytoskeletal structures and promoting
neuronal stability. Studies using double immunoﬂuorescent
G
 
microscopy and ultrastructural analysis revealed physiological
colocalization of gigaxonin with MAP1B in neurons.
Furthermore, in transfected cells the speciﬁc interaction of
gigaxonin with MAP1B is shown to enhance the microtubule
stability required for axonal transport over long distance. At
least two different mutations identiﬁed in GAN patients
(Bomont, P., L. Cavalier, F. Blondeau, C. Ben Hamida, S.
Belal, M. Tazir, E. Demir, H. Topaloglu, R. Korinthenberg,
B. Tuysuz, et al. 2000. 
 
Nat. Genet.
 
 26:370–374.) lead to
loss of gigaxonin–MAP1B-LC interaction. The devastating
axonal degeneration and neuronal death found in GAN
patients point to the importance of gigaxonin for neuronal
survival. Our ﬁndings may provide important insights into
the pathogenesis of neurodegenerative disorders related to
cytoskeletal abnormalities.
 
Introduction
 
The cytoskeleton network, which is responsible for cell
architecture,  intracellular transport, mitosis, cell motility,
and differentiation, is composed of microtubules, actin
microfilaments  (MFs), and intermediate filaments (IFs).*
Several lines of evidence have demonstrated that not only do
microtubules, actin microfilaments, and IFs interconnect
physically through cross-linking proteins, but the properties
of these networks can also be modulated by different associated
proteins (Houseweart and Cleveland, 1999; Fuchs and
Karakesisoglou, 2001). Cytoskeletal organization and dynamics
depend on protein self-associations and interactions with a
variety of binding partners such as microtubule-associated
proteins (MAPs) (Sanchez et al., 2000). MAP1B is one of
the major MAPs expressed in juvenile neurons. Since its initial
identification, the biological roles of MAP1B have been of
great interest. Acting as a complex of an NH
 
2
 
-terminal
heavy chain (HC; MAP1B-HC) and COOH-terminal light
chain (LC; MAP1B-LC), MAP1B is involved in many cellular
processes including morphogenesis, differentiation, and
maintenance of cytoskeletal integrity (for review see Tucker,
1990; Hirokawa, 1994). Several attempts including gene-
targeting studies have been made to determine MAP1B’s
role in brain development and functions (Edelmann et al.,
1996; Takei et al., 1997, 2000; Gonzalez-Billault et al.,
2000; Meixner et al., 2000; Teng et al., 2001). However,
the functional significance of interactions between MAP1B
and other proteins remains largely unclear. Intriguingly, a
growing body of evidence indicates that several human and
mouse diseases can be attributed to aberrant interactions
between cytoskeletons and their associated proteins (Garcia
and Cleveland, 2001).
Giant axonal neuropathy (GAN) is a severe recessive motor
and sensory neuropathy affecting both peripheral nerves and
the central nervous system (Berg et al., 1972). A prominent
pathological feature of GAN is the presence of giant axonal
swellings densely packed with aberrant IFs, abnormal micro-
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tubule network, and accumulation of other membranous or-
ganelles (Prineas et al., 1976; Bousquet, et al., 1996). The on-
set of disease symptoms usually occurs by age four and death
commonly follows in adolescence (Quvrier, 1989). The dis-
ease locus has been assigned to chromosome 16q24.1 (Ben
Hamída et al., 1997). Recently, Bomont et al. (2000) identi-
fied a novel gene (
 
GAN
 
) encoding gigaxonin. Out of 15 fami-
lies, 14 distinct 
 
GAN
 
 mutations were identified. The muta-
tions were distributed evenly throughout the coding sequence,
including one truncating mutation, four nonsense mutations
in the kelch repeat domain, and nine missense mutations over
the entire eleven coding exons. Although the discovery of the
 
GAN
 
 gene represents an important step toward elucidating
the pathogenesis of GAN, the molecular mechanisms under-
lying the abnormal cytoskeletons remains poorly understood.
Because alterations in the cytoskeletal network are a general
feature of several neurodegenerative disorders, including ALS
(Hirano, 1991; Williamson et al., 1996), understanding the
functions of gigaxonin may provide insights into the patho-
genesis of more prevalent degenerative disorders.
The presence of aberrant cytoskeletal networks in GAN
suggests that gigaxonin may function as a novel and distinct
cytoskeletal protein. In this report, we present in vivo and in
vitro evidence that identifies a neuronal binding partner for
gigaxonin. We found that through its kelch repeat domain
gigaxonin binds directly to the COOH end of MAP1B-LC,
an interaction that may regulate the activity of MAP1B
complex and enhances microtubule stability against depoly-
merizing reagents.
 
Results and discussion
 
Gigaxonin protein is expressed in brain and other tissues
 
The coding sequence of gigaxonin was amplified by PCR.
Northern blot analysis revealed a specific band of 4.6 kb
present in all tissues examined and prominent in brain,
heart, and muscle (unpublished data), demonstrating ubiq-
uitous expression of the gene. This result is consistent with
observations of multiple tissue pathologies in GAN pa-
tients. To characterize the function(s) of gigaxonin and de-
termine its protein expression, we raised a peptide-specific
antibody with an epitope at the COOH end. After con-
firming the specificity of the antibody, we analyzed gigaxo-
nin protein expression in mouse tissues by immunoblot as-
say. A single protein band of the expected size of 70 kD
was observed in brain, heart, and muscle tissues and in
transfected COS-7 cells, verifying the protein expression of
gigaxonin (Fig. 1).
 
Gigaxonin interacts directly with MAP1B-LC in vitro
 
Abnormal aggregation of multiple tissue-specific IFs in the
affected cells of GAN implicates a generalized disorder of cy-
toskeleton organization. We tested whether gigaxonin might
have the capacity to associate directly with cytoskeletal net-
works. To facilitate the assays, a HA epitope tag was engi-
neered at the NH
 
2
 
-terminal of the gigaxonin coding region.
The construct was transiently transfected into COS-7 cells,
and the protein was found to diffusely distribute throughout
the cytoplasm (Fig. 2 D), suggesting that the protein may
lack a direct cytoskeleton-binding site.
We set out to understand gigaxonin’s biological role by us-
ing the yeast two-hybrid system to identify proteins with
which gigaxonin interacts. The full-length gigaxonin was
fused to a GAL4 DNA-binding domain and used as the bait
to screen a human brain cDNA library. Identification of
multiple positive clones suggested that microtubule-associ-
ated protein 1B light chain (MAP1B-LC) is a neuronal bind-
ing partner for gigaxonin. Further assays were performed to
confirm this interaction. When full-length HA-gigaxonin
(HA-Gig-full) was cotransfected with flag-MAP1B-LC, the
gigaxonin staining pattern changed to a filamentous array
(Fig. 2 A) and the protein colocalized with MAP1B-LC along
the microtubule network (Fig. 2, B and C). Additional dou-
ble staining against tubulin and MAP1B-LC on gigaxonin–
MAP1B-LC–cotransfected cells confirmed that MAP1B-LC
aligns with microtubules (unpublished data). The direct in-
teraction between these two proteins was assessed by cotrans-
fection followed by coimmunoprecipitation. A specific band of
full-length gigaxonin that manifested exclusively in the co-
transfection lane and positive control lane (Fig. 2 E, lanes 1
and 5) confirmed the direct association between MAP1B-LC
and gigaxonin.
 
Gigaxonin physically colocalizes with MAP1B in neurons
 
The observed binding of gigaxonin to MAP1B-LC in vitro sug-
gested that the interaction might represent a biologically signif-
icant association. We sought to define MAP1B as a physiologi-
cal binding partner for gigaxonin in neurons in vivo by carrying
out double immunofluorescent microscopy on cultured DRG
neurons to test whether the two proteins colocalize. A gigaxo-
nin-specific antibody showed strong colabeling with MAP1B
(Fig. 3, A–C). The physical colocalization of the two proteins
in cultured neurons provided the first evidence of a correspond-
ing interaction in vivo. We then conducted coIP assays using
mouse brain tissue. The specific detection of gigaxonin from
the protein complex coimmunoprecipitated by anti–MAP1B-
LC antibody further confirmed the direct physiological associa-
tion between MAP1B-LC and gigaxonin (unpublished data).
Figure 1. Protein expression of gigaxonin. Proteins isolated from 
mouse tissues were analyzed by immunoblot with rabbit antigigaxonin 
(lanes 1–5) or mouse anti-HA (Covance) (lanes 6 and 7). The single 
band of  70 kD (lanes 1–4), which is absent in the untransfected 
COS-7 cells (lane 5), indicates the full-length gigaxonin protein. The 
40- and 28-kD bands from transfected COS-7 cells represent the 
COOH-terminal domain (Gig-C, lane 6) and NH2-terminal domain 
(Gig-N, lane 7), respectively. Migration of protein standard (Amersham 
Biosciences) is indicated at left. 
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To obtain in vivo evidence for this association at the ultrastruc-
tural level, we employed double immuno-EM labeling using
two different sizes of gold-conjugated particles and three sepa-
rate trials. Indeed, gigaxonin colocalized with MAP1B in
mouse sciatic nerves (Fig. 3 D). Approximately 43 
 
 
 
 7% of gi-
gaxonin labeling colocalizes with MAP1B, while 41 
 
 
 
 6% of
the MAP1B-associated gold particles were within 15 nm of gi-
gaxonin labeling. In contrast, no significant labeling of gigaxo-
nin and MAP1B was detected in negative control samples in
which only secondary antibodies were applied (Fig. 3 E). It is
interesting to note that the golden particles appeared to be asso-
ciated not only with filamentous cytoskeleton but also with
spherical structures. This implies that gigaxonin may also play a
role in connecting vesicles with cytoskeleton by interacting
with both MAP1B and certain vesicular-associated protein.
However, this implication awaits further investigations.
 
Gigaxonin competes with MAP1B-HC 
for binding to MAP1B-LC
 
To define more precisely the domains responsible for the as-
sociation of the two proteins, we first mapped gigaxonin’s
binding site for MAP1B-LC. HA epitope–tagged domains
of both NH
 
2
 
-terminal BTB and COOH-terminal kelch re-
peats of gigaxonin were examined. Immunoblot analysis
confirmed that both domains were stably expressed and were
of the expected size (Fig. 1, lanes 6 and 7). The COOH
kelch repeat domain of gigaxonin (Gig-C) coaligned with
MAP1B-LC in cotransfected cells (Fig. 4, A and B), sup-
porting the notion that the kelch repeat motif is important
for protein–protein interactions. In comparison, the BTB
domain was found to distribute diffusely in the cytoplasm
and failed to display specific associations (unpbulished data).
We then examined the NH
 
2
 
-terminal microtubule-binding
domain (MAP1B-LC-MTBD) and COOH terminus of
MAP1B-LC (MAP1B-LC-CT) in transfected COS-7 cells
to identify the target for gigaxonin association. We found
that the MAP1B-LC-CT displayed a staining pattern of
short actin stress filaments (Fig. 4 C), which is consistent
with published reports by others (Togel et al., 1998). In-
deed, gigaxonin’s kelch repeat domain colocalized with
MAP1B-LC-CT (Fig. 4 D). The results also revealed that
MAP1B-LC could bind to gigaxonin’s kelch repeat domain
Figure 2. Gigaxonin associates with MAP1B-LC 
on microtubules. The expression constructs of 
HA-Gig-full and flag-MAP1B-LC were cotransfected 
into COS-7 cells (A–D). The cells were subjected to 
double immunofluorescence as described previously 
(Yang et al., 1996). Antibodies are indicated in each 
panel: (A) Gig-full, (mouse anti-HA); (B) MAP1B-LC 
(rabbit anti-flag; Sigma-Aldrich). Note that gigaxonin 
displayed a network array that coaligned with 
MAP1B-LC in cotransfected cells (C), and a diffuse 
accumulation in cytoplasm in single transfected 
cells (D). Bar, 12  m. (E) The cotransfected cells 
were processed for coIP using anti-flag (MAP1B-LC) 
and immunoblotted with anti-HA (gigaxonin, Gig-F). 
Note the specific band of Gig-F present in cotransfection 
lane (lane 5) but absent in the single transfections of 
MAP1B-LC (lane 4) or Gig-F (lane 3). The total cell 
lysates from Gig-F single transfection without IP 
(lane 1) and untransfected COS-7 (lane 2) served as 
controls in this assay. 
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Figure 3. Gigaxonin physiologically colocalizes with MAP1B in neurons. (A–C) The cultured mouse DRG neurons were subjected to 
double immunofluorescence using anti–mouse MAP1B-LC (Sigma-Aldrich) (A, green) and rabbit antigigaxonin (B, red). Arrows denote 
colocalizations on cytoskeletal structures. Insets in A, B, and C show higher magnifications of the colocalization areas in the white 
boxes. (D) For double immuno EM, sciatic nerve samples were colabeled with rabbit antigigaxonin and mouse anti–MAP1B-LC followed 
by gold-conjugated secondary antibodies against mouse (small particles) and rabbit (large particles). The large particles represent 
gigaxonin, and the small particles identify MAP1B. Arrows identify colocalizations. The samples labeled with only secondary antibodies 
were used as negative control (E). Bar: (A–C) 20  m; (D and E) 200 nm. 
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without losing its ability to bind microtubules and actins.
Thus, through its kelch repeat domain gigaxonin interacts
directly with the COOH terminus of MAP1B-LC and asso-
ciates indirectly with cytoskeletal filaments.
MAP1B-LC harbors multiple binding sites for protein–
protein interactions at its COOH terminus including those
for gigaxonin and HC of MAP1B. We investigated whether
the association of MAP1B-LC with gigaxonin affects its in-
teraction with MAP1B-HC. When myc epitope–tagged
MAP1B-HC (MAP1B-HC-myc) was expressed alone in
COS-7 cells, the HC protein diffusely accumulated in the cy-
toplasm without filamentous appearance (unpublished data).
This finding is in agreement with reported findings (Togel et
al., 1998). However, when the HC was cotransfected with
MAP1B-LC into COS-7 cells, HC colocalized with LC on
microtubules (Fig. 4 E). Intriguingly, when the MAP1B-HC-
myc, flag-MAP1B-LC, and HA-gigaxonin were coexpressed
in triple transfected COS-7 cells, MAP1B-HC appeared in
five separate trials to compete with gigaxonin for binding to
MAP1B-LC. Although the LC remained bound to microtu-
bules, only one of the two proteins, either HC or gigaxonin,
could colocalize with LC on microtubules. In 
 
 
 
69% of the
triple transfected cells, the HC retained its association with
LC on microtubules (Fig. 4, F and G), whereas gigaxonin dif-
fusely distributed in cells (Fig. 4 H). The association of
MAP1B-LC with gigaxonin but not with HC could be only
observed in 
 
 
 
10% of the triple transfected cells (unpublished
data), suggesting that MAP1B-LC has a preferential associa-
tion with MAP1B-HC over gigaxonin. It has been suggested
that the HC might function as the regulatory subunit of the
MAP1B complex to control LC activity (Togel et al., 1998).
Our findings raise the possibility that through the competi-
tive binding to the LC with the HC, gigaxonin may play an
important role in regulating functions of the MAP1B com-
plex. A regulatory interaction between LC and HC of
MAP1B might be critical for normal functions of neurons.
 
The interaction of gigaxonin with MAP1B significantly 
enhances microtubule stability
 
To assess the functional significance of the interaction be-
tween MAP1B-LC and gigaxonin, we examined microtubule
stability in cells transfected either with MAP1B-LC alone or
MAP1B and gigaxonin together. The transfected cells were
treated with colchicine, a depolymerizing agent. In untrans-
fected control cells, all microtubules depolymerized within
15 min of colchicine treatment (Fig. 5 A). In agreement with
outside published reports, MAP1B had only a modest effect
on microtubule stabilization (Takemura et al., 1992; Togel et
al., 1998). After treatment for 30 min at concentrations up to
4.5 
 
 
 
M, a significant number of microtubule arrays (62%) in
82% of MAP1B-LC single transfected cells began to disap-
pear; within 60 min, no network was visible (Fig. 5 B). An
extraordinary feature of cells cotransfected with MAP1B-LC
and gigaxonin was that gigaxonin increased the ability of
MAP1B-LC to render the endogenous microtubule network
resistant to microtubule-destabilizing reagents. In 
 
 
 
70% of
MAP1B/gigaxonin double transfected cells, the microtubule
network remained intact even after a 90-min treatment with
colchicine. In a sizable number of double transfected cells
Figure 4. The kelch repeat domain of gigaxonin binds to the 
COOH terminus of MAP1B-LC. The cells were cotransfected for 
30 h with flag-MAP1B-LC and HA-Gig-C (A and B), or 
flag-MAP1B-LC-CT and HA-Gig-C (C and D), or flag-MAP1B-LC 
and MAP1B-HC-myc (E), or flag-MAP1B-LC, MAP1B-HC-myc, 
and HA-Gig-full (F–H). (A–D) Mouse anti-HA (Gig-C; B and D, 
red) and rabbit anti-flag (MAP1B-LC or MAP1B-LC-CT; A and C, 
green). Note that the Gig-C colocalized with MAP1B-LC-CT. 
(E and F) Sheep antitubulin (Cytoskeleton Inc.; E, red); mouse 
anti-myc (CLONTECH Laboratories, Inc.; E and F, green); rabbit 
anti-flag (F, red) and rabbit anti-myc (G, green); mouse anti-HA 
(H, red). Bar, 12  m. The diagram in I indicates that the kelch 
repeat domain of gigaxonin interacts with the COOH terminus of 
MAP1B-LC. 
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(37%), the association of gigaxonin with MAP1B-LC was
seen to protect microtubules against drug-induced disassem-
bly for 2 h (Fig. 5, C and D). All of the analyses on microtu-
bule stability were conducted on three independent experi-
ments. These findings reveal an important correlation
between gigaxonin–MAP1B interaction and microtubule sta-
bility in cultured cells. An integrated and well-stabilized neu-
ronal cytoskeleton is essential to neuronal survival.
 
Mutations in GAN disrupt the interaction of gigaxonin 
with MAP1B
 
To assess whether the mutations associated with GAN disrupt
the interaction of gigaxonin with MAP1B-LC, we used PCRs
to generate mutations in full-length gigaxonin. From the 14
mutations identified in GAN patients, we analyzed two muta-
tions for a possible loss of the specific gigaxonin–MAP1B-LC
interaction: the truncating mutation at the amino acid eight
and one nonsense mutation in the kelch repeat domain
(R293X). As judged by immunoblot analysis and immunoflu-
orescence microscopy of transfected cells, both mutations re-
sulted in unstable expression of the mutant proteins, undetect-
able level in the case of truncating mutation, and a greatly
decreased level in the nonsense mutation (unpublished data).
Of the few detectable cells transfected with HA epitope–tagged
R293X construct (HA-Gig-R293X), the R293X mutant pro-
tein was diffusely accumulated and had completely lost its asso-
ciation with MAB1B-LC (Fig. 5 E). Our results reveal that
through disruption of gigaxonin’s kelch repeat domain at least
2 out of the 14 distinct mutations can cause loss of gigaxonin–
MAP1B interaction. Moreover, the microtubules in cells
cotransfected with HA-Gig-R293X and flag-MAP1B-LC
failed to display the extraordinary stability seen in cells cotrans-
fected with wild-type gigaxonin and MAP1B-LC (Fig. 5 F).
Together, our data demonstrates that gigaxonin directly
associates with MAP1B-LC in the nervous system, an inter-
action that is disrupted by mutations identified in GAN pa-
tients. Gigaxonin–MAP1B-LC interaction renders microtu-
bules resistant to destabilizing reagents. We speculate that
through competing with MAP1B-HC for binding to the
MAP1B-LC, gigaxonin–MAP1B-LC interaction may regu-
late the association between LC and HC of MAP1B. The
identification of a neuronal binding partner for gigaxonin
serves as a prelude for future studies investigating the patho-
genesis of this disorder in vivo.
 
Materials and methods
 
Coimmunoprecipitation
 
The lysates of cells cotransfected with gigaxonin, or MAP1B-LC, or both
were incubated with anti-Flag beads (F7425; Sigma-Aldrich) at 4
 
 
 
C for 4 h
to capture the flag-MAP1B-LC and its associated protein. After washing,
Figure 5. The gigaxonin–MAP1B-LC 
interaction enhances microtubule 
stability. Both transfected and 
untransfected cells were double 
stained using antibodies indicated in 
each frame. After treatment with 
colchicine, the microtubules were 
seen to be depolymerized within 15 
min in untransfected (A) and within 60 
min in flag-MAP1B-LC single transfected 
cells (B). In contrast, the intact network 
could still be found in 20% of HA-Gig-full/
flag-MAP1B-LC cotransfected cells 
after 2 h treatment (C and D). Double 
immunostaining reveals that the 
HA-Gig-G293X (mutant gigaxonin, 
red) lost association with MAP1B-LC 
(E, green) and HA-Gig-G293X/flag-
MAP1B-LC displayed no enhancement 
of microtubule stability (F). Bar, 12  m. 
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the bound proteins were eluted with SDS sample buffer, analyzed via SDS-
PAGE, and immunoblotted with anti-HA antibody (Covance) to detect the
HA-gigaxonin. The proteins were visualized using ECL chemilumines-
cence (Amersham Biosciences).
 
Yeast two-hybrid screening
 
Full-length gigaxonin was subcloned in frame at the 3
 
 
 
 end of a GAL4
DNA-binding domain (DNA-BD) into pGBKT7 vector. The DNA–BD–
gigaxonin construct was transformed into the yeast strain, AH109, according
to the manufacturer’s instructions (CLONTECH Laboratories, Inc.). Immu-
noblots from the transformants were conducted to verify stable expression
of fusion protein. A concentrated overnight culture of AH109/DNA–BD–
gigaxonin was combined with a yeast culture of pretransformed MATCH-
MAKER human brain cDNA library. This mating mixture was incubated and
plated on selection plates. Transformant colonies growing on the plates
were then sorted and further analyzed for their putative positives.
 
Double immuno EM
 
Animals were killed by intravenous perfusion with 2% paraformaldehyde
and 0.05% glutaraldehyde. The dissected samples of sciatic nerves were
processed and embedded for EM (Coulombe et al., 1989). The antibody in-
corporations of mouse anti–MAP1B-LC (Sigma-Aldrich) and rabbit antigi-
gaxonin on ultrathin sections were visualized with 12 nm anti–rabbit and 6
nm anti–mouse gold-conjugated particles. After staining with uranyl ace-
tate, followed by lead citrate, the sections were analyzed under a Philips
CM10 microscope.
 
Neuron culture
 
The mice DRGs were microdissected and enzymatically dissociated by in-
cubating the tissues with 0.5% trypsin (Sigma-Aldrich) for 15–30 min at
37
 
 
 
C and then plated on coverslips coated with 0.02% collagen. Cells
were cultured in MEM medium containing NGF for 7 d. The cells were
then fixed and subjected to immunofluorescence staining as described
(Yang et al., 1996).
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